MedCity News
JUNE 11, 2023
The Making Care Primary Model will be tested by the Center for Medicare and Medicaid Innovation from July 1, 2024, to December 31, 2034, in Colorado, Massachusetts, Minnesota, New Jersey, New Mexico, New York, North Carolina and Washington.
European Pharmaceutical Review
JUNE 11, 2023
The US Food and Drug Administration (FDA) has approved commercial production at Bristol Myers Squibb’s newest cell therapy manufacturing facility in Devens, Massachusetts. The 244,000 square foot facility in Devens is BMS’ third commercial cell therapy facility in the US. It is located on the company’s existing Devens site, which has been developing, producing, and testing clinical and commercial medicines for over a decade.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
JUNE 11, 2023
Human tissues, coupled with AI that can deal with terabytes of data will blow mice models out of the water. With animal testing requirements finally removed, the pharma industry and its constituents can hope for faster innovation.
Copyright Clearance Center
JUNE 11, 2023
The post Make AI Your Writing Tutor appeared first on Copyright Clearance Center.
MedCity News
JUNE 11, 2023
During the annual meeting of the American Society of Clinical Oncology, a cell therapy posted clinical data during that could broaden its use in multiple myeloma. In other developments, the class of drugs called ADCs continue to make progress and a novel brain cancer drug has Phase 3 data that support its use as a new treatment option.
Pharmacy Times
JUNE 11, 2023
Denise Scarpelli, PharmD, MBA, discussed her presentation at the ASHP 2023 Summer Meeting.
Expert insights. Personalized for you.
106 
Let's personalize your content